Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) EBIT Margin (2021 - 2025)

Aligos Therapeutics filings provide 5 years of EBIT Margin readings, the most recent being 36186.98% for Q4 2025.

  • On a quarterly basis, EBIT Margin rose 3681010.0% to 36186.98% in Q4 2025 year-over-year; TTM through Dec 2025 was 229.41%, a 118461.0% increase, with the full-year FY2025 number at 229.41%, up 223954.0% from a year prior.
  • EBIT Margin hit 36186.98% in Q4 2025 for Aligos Therapeutics, up from 3827.4% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 36186.98% in Q4 2025 to a low of 17084.29% in Q1 2023.
  • Median EBIT Margin over the past 5 years was 1918.82% (2021), compared with a mean of 1242.26%.
  • Biggest five-year swings in EBIT Margin: crashed -1570128bps in 2023 and later surged 3681010bps in 2025.
  • Aligos Therapeutics' EBIT Margin stood at 10340.05% in 2021, then surged by 98bps to 163.1% in 2022, then tumbled by -693bps to 1294.03% in 2023, then surged by 52bps to 623.12% in 2024, then skyrocketed by 5907bps to 36186.98% in 2025.
  • The last three reported values for EBIT Margin were 36186.98% (Q4 2025), 3827.4% (Q3 2025), and 1924.04% (Q2 2025) per Business Quant data.